药学化合物a联合化合物b对人肝癌hepg2细胞作用机制研究本科论文.doc

沈 阳 药 科 大 学 本 科 毕 业 论 文 论文题目：化合物A联合 化合物 B对人肝癌HepG2细胞作用机制研究 起止时间：2014 年10月26日—2015年6月20日 姓名学号： 学院专业： 年级班级： 指导教师：XXX 副教授 实习单位：XXX大学生命科学与生物制药学院药理系 目 录 中文摘要······································································1英文摘要······································································2 第1章 绪论··································································3 1.1细胞凋亡·····························································3 1.2立题依据·····························································5 第2章 实验部分······························································6 2.1实验材料·····························································6 2.2实验方法·····························································7 2.3实验结果····························································12 第3章 结论与讨论···························································17 3.1结论································································17 3.2讨论································································18 参考文献·····································································21致谢·········································································23  摘 要 原发性肝癌是世界常见的恶性肿瘤之一，也是我国的高发恶性肿瘤，由于不易被早期诊断，进展迅速，术后容易复发、转移，因此预后较差。目前肝癌仍以外科手术为公认首选和主要的治疗手段，但由于很多肝癌患者确诊时已是中晚期，失去了手术治疗的机会并于诊断后1年内死亡，手术切除率30%，术后总体5年生存率仅30%~40%。对于可手术的肝癌患者，术后复发、转移是影响治疗效果及预后的主要因素，对于不能手术的中晚期肝癌患者尚缺乏有效的治疗方法。传统的化疗、放疗对肝癌疗效欠佳，目前仍缺乏行之有效的化学预防和治疗靶位[1]。因而本课题是对化合物 A联合化合物 B对人肝癌HepG2细胞作用机制研究。 本实验首先用MTT法分别测得不同浓度的A和B单独处理HepG2细胞及不同浓度的A和B联合用药处理HepG2细胞死亡的影响Abstract Hepatocellular carcinoma (HCC) is the most common cancer in the world and an increased malignant illness in our country. Because of its aggressive biological behavior, rapidly progresses and delayed diagnosis, this malignancy has a grim prognosis even following surgical resection and has high disease-recurrence. Surgery is the first and most common therapy of HCC. Unfortunately, the disease is usually detected at an ad